[炎症性疾病的磷酸二酯酶4靶向治疗进展]
[Progress in PDE4 targeted therapy for inflammatory diseases].
作者信息
Song Shun-de, Tang Hui-fang
机构信息
Zhejiang Respiratory Drugs Research Laboratory， Zhejiang University School of Medicine， Hangzhou 310058， China.
出版信息
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 May;43(3):353-8. doi: 10.3785/j.issn.1008-9292.2014.05.015.
cAMP-specific phosphodiesterase type 4 (PDE4) is one of the hot targets for treatment of inflammatory diseases. PDE4 inhibitors can suppress inflammation by increasing the concentration of cAMP in inflammatory cells. The efficacy and safety evaluations of several PDE4 inhibitors are currently carried on in clinical trials, for example GSK256066 in asthma, roflumilast and GSK256066 in chronic obstructive pulmonary disease, tetomilast in inflammatory bowel disease, and apremilast in dermatitis and arthritis etc. This article reviews the recent progress on PDE4-targeted therapy for inflammatory diseases.
环磷酸腺苷特异性4型磷酸二酯酶（PDE4）是治疗炎症性疾病的热门靶点之一。PDE4抑制剂可通过提高炎症细胞中环磷酸腺苷的浓度来抑制炎症。目前，几种PDE4抑制剂的疗效和安全性评估正在临床试验中进行，例如用于哮喘治疗的GSK256066、用于慢性阻塞性肺疾病治疗的罗氟司特和GSK256066、用于炎症性肠病治疗的替托司特以及用于皮炎和关节炎等治疗的阿普司特等。本文综述了炎症性疾病PDE4靶向治疗的最新进展。
Zotero 插件